#1 Clinical Trials Search in Europe

Belatacept

Belatacept is an innovative immunosuppressive drug being studied in clinical trials for kidney transplant recipients. It offers a potential alternative to traditional calcineurin inhibitors, with the aim of improving long-term kidney function and reducing side effects. This article summarizes key findings from recent clinical trials exploring the use of Belatacept in various kidney transplant scenarios.

Table of Contents

What is Belatacept?

Belatacept, also known by its brand name Nulojix, is a prescription medication used in transplant medicine, particularly for patients who have received kidney transplants[1]. It belongs to a class of drugs called immunosuppressants, which help prevent the body’s immune system from rejecting the transplanted organ[2].

Belatacept was approved by the United States Food and Drug Administration (FDA) in 2011 for use in adult kidney transplant recipients[1]. It offers an alternative to traditional immunosuppressant medications, such as calcineurin inhibitors (CNIs) like cyclosporine and tacrolimus[3].

How Belatacept Works

Belatacept works by inhibiting a process called costimulation in the immune system. Specifically, it targets and blocks a protein called CD86 on certain immune cells[4]. By doing this, Belatacept helps to prevent the activation of T-cells, which are a type of white blood cell responsible for recognizing and attacking foreign substances in the body, including transplanted organs.

This mechanism of action is different from traditional immunosuppressants like calcineurin inhibitors. By using a different pathway to suppress the immune system, Belatacept may offer some advantages over these older medications[3].

Conditions Treated with Belatacept

Belatacept is primarily used in the following conditions:

  • Kidney Transplantation: This is the main use of Belatacept. It helps prevent rejection in patients who have received a kidney transplant[1].
  • Heart Transplantation: Some research is exploring the use of Belatacept in heart transplant patients, especially those at risk of chronic kidney failure[3].
  • Pancreas Transplantation: Studies are investigating the use of Belatacept in patients who have received a pancreas transplant[5].

How Belatacept is Administered

Belatacept is given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The dosing schedule typically follows this pattern:

  1. Initial phase: Higher doses are given more frequently, usually every two weeks for the first month or two after transplant[1].
  2. Maintenance phase: After the initial phase, the dose is usually reduced and given less frequently, typically once every four weeks[6].

Some research is exploring whether the maintenance dose can be given even less frequently, such as every eight weeks, in stable patients[6]. However, this is still being studied and is not the standard practice.

Benefits of Belatacept

Belatacept offers several potential benefits for transplant patients:

  • Kidney Function: Belatacept may help preserve kidney function better than some traditional immunosuppressants. This is particularly important for kidney transplant patients[3].
  • Reduced Nephrotoxicity: Unlike calcineurin inhibitors, Belatacept is not toxic to the kidneys. This makes it a good option for patients with or at risk of kidney problems[3].
  • Lower Risk of Donor-Specific Antibodies: Some studies suggest that patients on Belatacept may be less likely to develop antibodies against the donor organ, which can lead to rejection[1].
  • Potential for Less Frequent Dosing: While most patients receive Belatacept every four weeks, some research is exploring whether stable patients can receive it less frequently[6].

Potential Side Effects and Risks

Like all medications, Belatacept can cause side effects. Some potential risks and side effects include:

  • Increased Risk of Infections: Because Belatacept suppresses the immune system, it can increase the risk of various infections[7].
  • Risk of Rejection: While Belatacept is designed to prevent rejection, some studies have found a higher rate of acute rejection in the early period after transplant compared to traditional medications[3].
  • Post-Transplant Lymphoproliferative Disorder (PTLD): This is a type of cancer that can occur in transplant patients. The risk may be higher with Belatacept, especially in patients who have never been exposed to Epstein-Barr virus[1].

It’s important to discuss all potential risks and benefits with your healthcare provider.

Ongoing Research and Future Directions

Research on Belatacept is ongoing, with several areas of focus:

  • Use in Other Organ Transplants: While primarily used in kidney transplants, research is exploring its use in heart and pancreas transplants[3][5].
  • Optimizing Dosing Schedules: Studies are investigating whether some patients can receive Belatacept less frequently, such as every 8 weeks instead of every 4 weeks[6].
  • Use in Pediatric Patients: Research is being conducted to understand how Belatacept works in adolescent kidney transplant recipients[4].
  • Treatment of Proteinuria: Some studies are exploring whether Belatacept can help reduce protein in the urine (proteinuria) in kidney transplant patients[8].

These ongoing studies aim to further our understanding of Belatacept and potentially expand its use to benefit more transplant patients.

Aspect Details
Primary Use Prevention of kidney transplant rejection
Administration Intravenous infusion, typically 5-10 mg/kg
Dosing Schedule Initially every 2-4 weeks, then monthly for maintenance
Potential Benefits Improved long-term kidney function, reduced nephrotoxicity, lower risk of donor-specific antibodies
Study Populations Varies by trial; includes stable transplant recipients, those with CNI toxicity, and patients with mild immunological risk factors
Key Outcomes Measured Kidney function (eGFR), proteinuria, rejection rates, donor-specific antibodies, patient and graft survival
Safety Considerations Risk of infections, potential for rejection, need for close monitoring
Ongoing Research Optimal dosing schedules, conversion from other immunosuppressants, use in specific patient subgroups

FAQ

  • What is Belatacept? Belatacept is a prescription medication used to prevent organ rejection in kidney transplant recipients. It works by suppressing the immune system's response to the transplanted kidney.
  • How is Belatacept administered? Belatacept is given as an intravenous infusion, typically at a dose of 5-10 mg/kg. The frequency of administration varies, but common schedules include every 2-4 weeks initially, then monthly for maintenance therapy.
  • What are the potential benefits of Belatacept over traditional immunosuppressants? Belatacept may offer improved long-term kidney function, reduced nephrotoxicity, and a lower risk of developing donor-specific antibodies compared to calcineurin inhibitors like tacrolimus or cyclosporine.
  • Who might be a candidate for Belatacept therapy? Candidates may include kidney transplant recipients with calcineurin inhibitor toxicity, those at risk for long-term kidney damage, or patients with mild to moderate immunological risk factors. Specific eligibility criteria vary by study.
  • What are some potential side effects or risks of Belatacept? Potential risks include an increased chance of certain infections or cancers due to immunosuppression. Some studies are also evaluating the risk of transplant rejection compared to standard therapies. Close monitoring is required during treatment.

Ongoing Clinical Trials on Belatacept

  • Study of Belatacept versus Tacrolimus in Kidney Transplant Recipients with Subclinical Antibody Mediated Rejection

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of belatacept, tacrolimus and ciclosporin in heart transplant patients at risk of kidney failure

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on the Effects of Belatacept, Ciclosporin, and Tacrolimus on Blood Vessel Health in Kidney Transplant Patients

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Switching from Tacrolimus or Ciclosporin to Belatacept for Adolescents with Kidney Transplants

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain

  • Belatacept Dose Reduction Safety in Kidney Transplant Recipients with a Well-Matched Donor

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Austria

  • Study on the Safety and Effectiveness of Tacrolimus and Drug Combination for Patients with BK Polyomavirus Infection After Kidney Transplantation

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Germany

  • Study on Replacing CNIs with Belatacept for Kidney Transplant Patients with Early Graft Dysfunction 3 to 12 Months Post-Transplant

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

Glossary

  • Belatacept: An immunosuppressive drug used to prevent organ rejection in kidney transplant recipients by blocking a specific pathway in T cell activation.
  • Calcineurin inhibitor (CNI): A class of immunosuppressive drugs, including tacrolimus and cyclosporine, commonly used in transplant recipients but associated with kidney toxicity.
  • Donor-specific antibodies (DSA): Antibodies produced by the transplant recipient that specifically target the donor's human leukocyte antigens (HLAs), potentially leading to organ rejection.
  • Estimated glomerular filtration rate (eGFR): A measure of kidney function calculated using blood tests, age, sex, and race. Lower eGFR indicates decreased kidney function.
  • Proteinuria: The presence of excess proteins in the urine, which can be a sign of kidney damage or dysfunction in transplant recipients.
  • Biopsy-proven rejection: Confirmation of transplant rejection through examination of a small tissue sample taken from the transplanted kidney.
  • Immunosuppression: The intentional reduction of the body's immune response, used to prevent organ rejection in transplant recipients.
  • Monotherapy: The use of a single drug for treatment, in this context referring to the use of Belatacept as the primary immunosuppressive medication.

References

  1. https://clinicaltrials.gov/study/NCT01953120
  2. https://clinicaltrials.gov/study/NCT02939365
  3. https://clinicaltrials.eu/trial/study-on-belatacept-for-heart-transplant-patients-at-risk-of-chronic-kidney-disease-with-tacrolimus-and-ciclosporin-drug-combination/
  4. https://clinicaltrials.gov/study/NCT01791491
  5. https://clinicaltrials.gov/study/NCT02103855
  6. https://clinicaltrials.gov/study/NCT02560558
  7. https://clinicaltrials.gov/study/NCT02078193
  8. https://clinicaltrials.gov/study/NCT02327403